NEW YORK, Feb. 13 (GenomeWeb News) - Proteome Sciences has won
€438,000 ($563,000) from the European Union, and £419,000 ($794,000) from the UK government, to conduct research into anti-depressant drugs and into Alzheimer's disease, respectively, the company said today.
The EU award is part of a €7.5 million, three-year multi-center pharmacogenomics grant from the EU's 6th Framework Program. Proteome Sciences will explore patients' response to anti-depressants, with the aim to predict responders, find early disease indicators, and discover new drug targets.
The UK government grant, jointly awarded to Cobham, UK-based Proteome Sciences and the Institute of Psychiatry at Kings College, London, will fund the discovery of new biomarkers and targets for Alzheimer's.